DANZITEN vs TABRECTA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 7, 2026·How we rate

Possible drug interaction. DANZITEN and TABRECTA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	DANZITEN	TABRECTA
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	NILOTINIB TARTRATE	CAPMATINIB HYDROCHLORIDE
Manufacturer	Azurity	Novartis
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Treats	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors	Non-Small-Cell Lung Carcinoma

danziten tabrecta

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

NILOTINIB TARTRATE

CAPMATINIB HYDROCHLORIDE

Manufacturer

Azurity

Novartis

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Danziten or Tabrecta?

By our independent rating, Danziten scores higher — 3.6 vs 3.5 out of 5 for Tabrecta. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Danziten and Tabrecta?

Danziten contains Nilotinib Tartrate, while Tabrecta contains Capmatinib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.